CA2835591A1 - Immunoglobulin variants and uses thereof - Google Patents

Immunoglobulin variants and uses thereof Download PDF

Info

Publication number: CA2835591A1
Authority: CA; Canada
Prior art keywords: antibody; cells; cell; binding; seq
Prior art date: 2002-12-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA2835591A

Other languages

English (en)

French (fr)

Inventor

Camellia W. Adams

Andrew C. Chan

Craig W. Crowley

Henry B. Lowman

Gerald R. Nakamura

Leonard G. Presta

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Genentech Inc

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-16

Filing date

2003-12-16

Publication date

2004-07-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36166967&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2835591(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-12-16 Application filed by Genentech Inc filed Critical Genentech Inc

2003-12-16 Priority claimed from CA2507898A external-priority patent/CA2507898C/en

2004-07-08 Publication of CA2835591A1 publication Critical patent/CA2835591A1/en

Status Abandoned legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Microbiology (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physics & Mathematics (AREA)
Cell Biology (AREA)
Plant Pathology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CA2835591A 2002-12-16 2003-12-16 Immunoglobulin variants and uses thereof Abandoned CA2835591A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US43411502P	2002-12-16	2002-12-16
US60/434,115		2002-12-16
US52616303P	2003-12-01	2003-12-01
US60/526,163		2003-12-01
CA2507898A CA2507898C (en)	2002-12-16	2003-12-16	Immunoglobulin variants and uses thereof

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2507898A Division CA2507898C (en)	2002-12-16	2003-12-16	Immunoglobulin variants and uses thereof

Publications (1)

Publication Number	Publication Date
CA2835591A1 true CA2835591A1 (en)	2004-07-08

Family

ID=36166967

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2835591A Abandoned CA2835591A1 (en)	2002-12-16	2003-12-16	Immunoglobulin variants and uses thereof

Country Status (6)

Country	Link
CN (6)	CN1748143A (no)
CA (1)	CA2835591A1 (no)
CL (1)	CL2003002639A1 (no)
NO (1)	NO338313B1 (no)
TN (1)	TNSN06133A1 (no)
ZA (1)	ZA200504221B (no)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013085893A1 (en)	2011-12-05	2013-06-13	Immunomedics, Inc.	Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
CN111202844A (zh) *	2012-08-31	2020-05-29	拜尔健康护理有限责任公司	抗催乳素受体抗体制剂

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2591059C (en)	2004-12-28	2018-11-06	Innate Pharma	Monoclonal antibodies against nkg2a
BRPI0712953B8 (pt)	2006-06-30	2021-05-25	Novo Nordisk As	anticorpos anti-nkg2a, seu uso, e composição farmacêutica
CN101952317B (zh)	2008-01-24	2015-07-22	诺沃-诺迪斯克有限公司	人化抗-人nkg2a单克隆抗体
WO2010093480A2 (en) *	2009-02-16	2010-08-19	Biolex Therapeutics, Inc.	Humanized anti-cd20 antibodies and methods of use
JP5874881B2 (ja)	2009-10-06	2016-03-02	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	遺伝子改変されたマウスおよび移植方法
CN102190728B (zh)	2010-03-17	2014-07-02	永卓博济(上海)生物医药技术有限公司	一种人源化抗cd20单克隆抗体
MX350385B (es) *	2011-02-15	2017-09-04	Regeneron Pharma	Ratones de m-csf humanizada.
EP2721068B1 (en)	2011-06-17	2018-12-05	Novo Nordisk A/S	Selective elimination of erosive cells
PT2771364T (pt) *	2011-10-27	2019-09-10	Genmab As	Produção de proteínas heterodiméricas
CN103880958B (zh) *	2014-03-27	2016-01-20	安徽大学	抗cd20抗原的抗体l4h6及其应用
CN103897059B (zh) *	2014-03-27	2016-03-23	中国人民解放军军事医学科学院生物工程研究所	抗cd20抗原的抗体l5h7及其应用
CN103880957B (zh) *	2014-03-27	2016-01-20	安徽大学	抗cd20抗原的抗体l1h1及其应用
CN103936855B (zh) *	2014-03-27	2016-05-04	合肥泰瑞生物技术有限公司	抗cd20抗原的抗体l4h5及其应用
CN103936858B (zh) *	2014-03-27	2016-05-04	安徽大学	抗cd20抗原的抗体l5h6及其应用
PT3282835T (pt)	2015-04-13	2023-07-25	Univ Yale	Ratinhos knockin de sirpa-il15 humanizadas e métodos de utilização dos mesmos
JP7134944B2 (ja) *	2016-08-11	2022-09-12	ザジャクソンラボラトリー	遺伝子改変免疫不全非ヒト動物における改良されたヒト赤血球生存に関連する方法および組成物
CN106872713A (zh) *	2016-12-27	2017-06-20	许洋	一种微量蛋白质原位检测的免疫质谱试剂盒及制备方法
CN108531561A (zh) *	2017-03-01	2018-09-14	云南序源生物技术开发有限公司	一种快速检测用于鉴定y染色体单倍型谱系的snp特征位点的试剂盒及方法
CN111705084B (zh) *	2020-08-18	2020-12-08	江苏集萃药康生物科技有限公司	一种稳定表达荧光素酶及人cd20敲除鼠cd20的小鼠b细胞淋巴瘤细胞系构建方法
CN114990128A (zh) *	2021-06-16	2022-09-02	百奥赛图(北京)医药科技股份有限公司	Cd20基因人源化非人动物的构建方法及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5576195A (en) *	1985-11-01	1996-11-19	Xoma Corporation	Vectors with pectate lyase signal sequence
DK1974747T3 (da) *	1998-08-11	2012-09-17	Biogen Idec Inc	Kombinationsterapier for B-celle-lymfomer omfattende indgivelse af anti-CD20-antistof
MXPA03002262A (es) *	2000-09-18	2003-10-15	Idec Pharma Corp	Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
US20020128448A1 (en) *	2000-10-20	2002-09-12	Idec Pharmaceuticals Corporation	Variant IgG3 Rituxan and therapeutic use thereof

2003
- 2003-12-11 CN CNA2003801096904A patent/CN1748143A/zh active Pending
- 2003-12-11 CN CNA2003801063031A patent/CN1751236A/zh active Pending
- 2003-12-16 CN CNB200380109682XA patent/CN100460421C/zh not_active Expired - Lifetime
- 2003-12-16 CL CL200302639A patent/CL2003002639A1/es unknown
- 2003-12-16 CN CNA2008101748175A patent/CN101418045A/zh active Pending
- 2003-12-16 CN CN200810174816.0A patent/CN101418044B/zh not_active Expired - Lifetime
- 2003-12-16 CN CNA2008101748156A patent/CN101418043A/zh active Pending
- 2003-12-16 CA CA2835591A patent/CA2835591A1/en not_active Abandoned
2005
- 2005-05-24 ZA ZA200504221A patent/ZA200504221B/en unknown
2006
- 2006-05-10 TN TNP2006000133A patent/TNSN06133A1/en unknown
2015
- 2015-02-20 NO NO20150245A patent/NO338313B1/no not_active IP Right Cessation

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013085893A1 (en)	2011-12-05	2013-06-13	Immunomedics, Inc.	Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
EP2788020A1 (en) *	2011-12-05	2014-10-15	Immunomedics, Inc.	Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
EP2788020A4 (en) *	2011-12-05	2015-04-29	Immunomedics Inc	THERAPEUTIC USE OF ANTI-CD22 ANTIBODIES FOR THE INDUCTION OF TROGO CYTOSIS
US9192664B2 (en)	2011-12-05	2015-11-24	Immunomedics, Inc.	Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
US9475883B2 (en)	2011-12-05	2016-10-25	Immunomedics, Inc.	Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
US9663576B2 (en)	2011-12-05	2017-05-30	Immunomedics, Inc.	Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
US9963507B2 (en)	2011-12-05	2018-05-08	Immunomedics, Inc.	Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
CN111202844A (zh) *	2012-08-31	2020-05-29	拜尔健康护理有限责任公司	抗催乳素受体抗体制剂
CN111202843A (zh) *	2012-08-31	2020-05-29	拜尔健康护理有限责任公司	抗催乳素受体抗体制剂

Also Published As

Publication number	Publication date
CL2003002639A1 (es)	2005-04-08
NO338313B1 (no)	2016-08-08
CN101418043A (zh)	2009-04-29
CN101418044A (zh)	2009-04-29
CN101418045A (zh)	2009-04-29
CN101418044B (zh)	2014-03-12
CN100460421C (zh)	2009-02-11
ZA200504221B (en)	2006-08-30
CN1751236A (zh)	2006-03-22
CN1747969A (zh)	2006-03-15
TNSN06133A1 (en)	2007-11-15
NO20150245L (no)	2005-08-31
CN1748143A (zh)	2006-03-15

Legal Events

Date	Code	Title	Description
2013-12-24	EEER	Examination request	Effective date: 20131129
2014-07-24	EEER	Examination request	Effective date: 20131129
2016-09-04	FZDE	Dead	Effective date: 20160722

Publication	Publication Date	Title
US20220002430A1 (en)	2022-01-06	Immunoglobulin variants and uses thereof
US20100280227A1 (en)	2010-11-04	Polypeptides that bind br3 and uses thereof
CA2835591A1 (en)	2004-07-08	Immunoglobulin variants and uses thereof
JP2008529499A (ja)	2008-08-07	抗体変異体とその使用
AU2017202590A1 (en)	2017-05-18	Immunoglobulin variants and uses thereof